Formulated Palmitoylethanolamide Supplementation Improves Parameters of Cognitive Function and BDNF Levels in Young, Healthy Adults: A Randomised Cross-Over Trial.

ABSTRACT:

Background

Palmitoylethanolamide (PEA) is an endocannabinoid-like lipid mediator which is naturally produced in the body and found in certain foods. The aim of this study was to assess the effect of a bioavailable formulated form of PEA (Levagen+^®) on serum BDNF levels and parameters of cognitive function in healthy adults.

Methods

A randomised double-blinded placebo-controlled cross-over trial was implemented to measure the effects of a 6-week 700 mg/day course of formulated PEA supplementation versus a placebo. Participants (n = 39) completed pre- and post-assessments of a lab-based cognitive test. Serum samples were collected to measure BDNF concentrations using an immunoassay.

Results

A significant increase in serum BDNF levels was found following PEA s

SUBMITTER: Kim N 

PROVIDER: S-EPMC10891801 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature